Search research articles
Contact Us
Filters
Showing results (91-100 of 136) with videos related to
Page
of 14
Sort By:
Blood Cancer Journal
|
May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E Perl, Naoko Hosono, Pau Montesinos, et al.
European Journal of Haematology
|
January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia
Xavier Cahu, Martin Carré, Christian Recher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2017
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission
Xavier Thomas, Stéphane de Botton, Sylvie Chevret, et al.
Leukemia
|
July 17, 2024
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study
Corentin Orvain, Sarah Bertoli, Pierre Peterlin, et al.
Leukemia Research
|
December 20, 2014
Azacitidine for the treatment of relapsed and refractory AML in older patients
Raphael Itzykson, Sylvain Thépot, Céline Berthon, et al.
Lancet (London, England)
|
April 16, 2016
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag, Serge Koscielny, Jacques Bosq, et al.
European Journal of Haematology
|
March 18, 2021
Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status
Claire Jouzier, Jean-François Hamel, Pierre-Yves Dumas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B
Thierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, et al.
Leukemia & Lymphoma
|
April 28, 2016
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies
Sylvain Pilorge, Stephanie Harel, Vincent Ribrag, et al.
Page
of 14
Search research articles
Search
Showing results (91-100 of 136) with videos related to
Sort By:
Page
of 14
Blood Cancer Journal
|
May 31, 2022
Clinical outcomes in patients with relapsed/refractory FLT3-mutated acute myeloid leukemia treated with gilteritinib who received prior midostaurin or sorafenib
Alexander E Perl, Naoko Hosono, Pau Montesinos, et al.
European Journal of Haematology
|
January 26, 2017
Impact of body-surface area on patients' outcome in younger adults with acute myeloid leukemia
Xavier Cahu, Martin Carré, Christian Recher, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
February 22, 2017
Randomized Phase II Study of Clofarabine-Based Consolidation for Younger Adults With Acute Myeloid Leukemia in First Remission
Xavier Thomas, Stéphane de Botton, Sylvie Chevret, et al.
Leukemia
|
July 17, 2024
Molecular relapse after first-line intensive therapy in patients with CBF or NPM1-mutated acute myeloid leukemia - a FILO study
Corentin Orvain, Sarah Bertoli, Pierre Peterlin, et al.
Leukemia Research
|
December 20, 2014
Azacitidine for the treatment of relapsed and refractory AML in older patients
Raphael Itzykson, Sylvain Thépot, Céline Berthon, et al.
Lancet (London, England)
|
April 16, 2016
Rituximab and dose-dense chemotherapy for adults with Burkitt's lymphoma: a randomised, controlled, open-label, phase 3 trial
Vincent Ribrag, Serge Koscielny, Jacques Bosq, et al.
European Journal of Haematology
|
March 18, 2021
Conventional chemotherapy for acute myeloid leukemia in older adults: Impact on nutritional, cognitive, and functional status
Claire Jouzier, Jean-François Hamel, Pierre-Yves Dumas, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
December 15, 2021
Measurable Residual Disease Response and Prognosis in Treatment-Naïve Acute Myeloid Leukemia With Venetoclax and Azacitidine
Keith W Pratz, Brian A Jonas, Vinod Pullarkat, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
November 12, 2014
Young patients with non-germinal center B-cell-like diffuse large B-cell lymphoma benefit from intensified chemotherapy with ACVBP plus rituximab compared with CHOP plus rituximab: analysis of data from the Groupe d'Etudes des Lymphomes de l'Adulte/lymphoma study association phase III trial LNH 03-2B
Thierry Jo Molina, Danielle Canioni, Christiane Copie-Bergman, et al.
Leukemia & Lymphoma
|
April 28, 2016
Primary bone diffuse large B-cell lymphoma: a retrospective evaluation on 76 cases from French institutional and LYSA studies
Sylvain Pilorge, Stephanie Harel, Vincent Ribrag, et al.
Page
of 14